• Ryota Hase, Yoshiaki Yokoyama, Hiroyuki Suzuki, Shunsuke Uno, Takahiro Mikawa, Daisuke Suzuki, Kiyoharu Muranaka, and Naoto Hosokawa.
• Department of Infectious Diseases, Kameda Medical Center, Chiba, Japan; Department of Infectious Diseases, Japanese Red Cross Narita Hospital, Chiba, Japan. Electronic address: hase.ryota@kameda.jp.
• Int. J. Infect. Dis. 2020 Jun 1; 95: 210-215.

ObjectivesThe infectious diseases team at Kameda Medical Center, Japan, implemented a new outpatient parenteral antimicrobial therapy (OPAT) program in July 2012 and expanded the program with the support of home care services. This study reviews the OPAT program after 5.5 years of operation.MethodsWe prospectively collected data about the age, sex, diagnoses, causative organisms, types of OPAT, modes of administration, selected antibiotics, treatment durations, bed days saved, outcomes, readmissions, and estimated cost reductions of all patients who were treated in the OPAT program from July 2012 to December 2017.ResultsOf the 66 patients treated under the OPAT program, 45 (68.2%) were treated using clinic OPAT, and 21 (31.8%) were treated using homecare OPAT. The most commonly targeted organism was methicillin-susceptible Staphylococcus aureus. Continuous infusion with elastomeric pumps was employed in 55 patients (83.3%). Cefazolin was the most frequently used antibiotic (39.4%), followed by penicillin G (24.2%). The median OPAT duration was 13 days (range, 3-51), and the total bed days saved was 923. The estimated medical cost reduction was approximately 87,000 US dollars.ConclusionsOur experience shows that OPAT is a safe and feasible practice not only for efficient bed utilization and medical cost savings but also for better antimicrobial stewardship.Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.

22 keywords...

hide…